Catalyst Pharmaceuticals, Inc. (CPRX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Catalyst Pharmaceuticals, Inc.

IDEAYA Biosciences, Inc.

Vericel Corp.

Springworks Therapeutics, Inc.

Taro Pharmaceutical Industries Ltd.

Ironwood Pharmaceuticals, Inc.

CureVac NV

Pacira Biosciences, Inc.

Agios Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.

Why is Catalyst Pharmaceuticals, Inc. ?

High Management Efficiency with a high ROE of 25.28%

Company has a low Debt to Equity ratio (avg) at times

Healthy long term growth as Net Sales has grown by an annual rate of 36.06% and Operating profit at 41.55%

The company has declared Positive results for the last 4 consecutive quarters

OPERATING CASH FLOW(Y) Highest at USD 275.09 MM
NET PROFIT(HY) At USD 108.96 MM has Grown at 63.51%
RAW MATERIAL COST(Y) Fallen by 0.34% (YoY)

With ROE of 23.98%, it has a very attractive valuation with a 3.97 Price to Book Value

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 11.33%, its profits have risen by 188.5% ; the PEG ratio of the company is 0.1

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Catalyst Pharmaceuticals, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Catalyst Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Catalyst Pharmaceuticals, Inc.

6.31%

1.26

40.29%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

36.06%

EBIT Growth (5y)

41.55%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.73

Sales to Capital Employed (avg)

0.77

Tax Ratio

23.64%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

86.94%

ROCE (avg)

116.28%

ROE (avg)

25.28%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.97

EV to EBIT

11.13

EV to EBITDA

9.56

EV to Capital Employed

12.03

EV to Sales

4.82

PEG Ratio

0.11

Dividend Yield

ROCE (Latest)

108.10%

ROE (Latest)

23.98%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

18What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 275.09 MM

NET PROFIT(HY)

At USD 108.96 MM has Grown at 63.51%

RAW MATERIAL COST(Y)

Fallen by 0.34% (YoY

CASH AND EQV(HY)

Highest at USD 1,233.46 MM

DEBT-EQUITY RATIO (HY)

Lowest at -75.91 %

NET SALES(Q)

Highest at USD 146.56 MM

OPERATING PROFIT(Q)

Highest at USD 75.76 MM

PRE-TAX PROFIT(Q)

Highest at USD 72.25 MM

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Here's what is working for Catalyst Pharmaceuticals, Inc.

Operating Cash Flow

Highest at USD 275.09 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Profit

At USD 108.96 MM has Grown at 63.51%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Net Sales

Highest at USD 146.56 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Operating Profit

Highest at USD 75.76 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit

Highest at USD 72.25 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Cash and Eqv

Highest at USD 1,233.46 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -75.91 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by 0.34% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Catalyst Pharmaceuticals, Inc.

Non Operating Income

Highest at USD 0.09 MM

in the last five periods

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating income